
IBO
Impact Biomedical Inc
- Overview
- Forecast
- Valuation

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.559
Open
0.530
VWAP
0.53
Vol
459.67K
Mkt Cap
6.21M
Low
0.5135
Amount
245.36K
EV/EBITDA(TTM)
--
Total Shares
12.09M
EV
16.21M
EV/OCF(TTM)
--
P/S(TTM)
--
Impact Biomedical Inc. is a human healthcare company and is a wholly owned subsidiary of DSS, Inc. The Company, through the utilization of its intellectual property rights, or through investment in, or through acquisition of companies in the bio health and biomedical fields, focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The Company, through its subsidiary, Global BioLife, Inc., focuses on research in four main areas: the Linebacker project, which develops a universal therapeutic drug platform; a new sugar substitute called Laetose; a multi-use fragrance called 3F (Functional Fragrance Formulation), which is a mosquito fragrance product; and Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.
Show More
Valuation Metrics
The current forward P/E ratio for Impact Biomedical Inc (IBO.A) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Impact Biomedical Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2024Q4
N/A
Total Revenue
FY2024Q4
YoY :
-23.18%
-875.00K
Operating Profit
FY2024Q4
YoY :
+2051.70%
-27.13M
Net Income after Tax
FY2024Q4
YoY :
+2045.45%
-2.36
EPS - Diluted
FY2024Q4
YoY :
+190.07%
-1.26M
Free Cash Flow
FY2024Q4
N/A
Gross Profit Margin - %
FY2024Q4
N/A
FCF Margin - %
FY2024Q4
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
7.3M
USD
11
3-6
Months
58.0
USD
1
6-9
Months
17.0K
USD
3
0-12
Months
0.0
USD
0
Bought
0-3
1
310.0
USD
Months
3-6
0
0.0
USD
Months
6-9
5
159.6K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
7.3M
USD
11
3-6
Months
58.0
USD
1
6-9
Months
17.0K
USD
3
0-12
Months
0.0
USD
0
Bought
0-3
1
310.0
USD
Months
3-6
0
0.0
USD
Months
6-9
5
159.6K
USD
Months
0-12
0
0.0
USD
Months
IBO News & Events
Events Timeline
2025-02-26 (ET)
2025-02-26
08:40:42
Impact BioMedical announces acquisition of Celios in $1.15M equity transaction

2025-02-26
08:36:20
DSS announces sale of Celios to Impact BioMedical

2024-11-19 (ET)
2024-11-19
07:09:05
Impact BioMedical CEO says 'well-positioned' to drive long-term value

Sign Up For More Events
Sign Up For More Events
News
2.0
05-05BenzingaWhy Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
4.5
05-02BenzingaS&P 500 Gains 1%; April Jobs Top Expectations
4.5
04-04BenzingaDow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March
Sign Up For More News
People Also Watch

MSFT
Microsoft Corp
453.130
USD
+0.04%

AMZN
Amazon.com Inc
205.170
USD
-2.42%

NVDA
NVIDIA Corp
134.830
USD
-0.38%

AVGO
Broadcom Inc
232.640
USD
+0.22%

WMT
Walmart Inc
96.350
USD
-0.50%

AAPL
Apple Inc
211.450
USD
-0.41%

TSLA
Tesla Inc
342.820
USD
-1.40%

META
Meta Platforms Inc
643.880
USD
-2.35%

XOM
Exxon Mobil Corp
108.580
USD
+0.09%

ORCL
Oracle Corp
159.400
USD
-2.18%
FAQ

What is Impact Biomedical Inc (IBO) stock price today?
The current price of IBO is 0.5139 USD — it has decreased -1.34 % in the last trading day.

What is Impact Biomedical Inc (IBO)'s business?

What is the price predicton of IBO Stock?

What is Impact Biomedical Inc (IBO)'s revenue for the last quarter?

What is Impact Biomedical Inc (IBO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Impact Biomedical Inc (IBO)'s fundamentals?

How many employees does Impact Biomedical Inc (IBO). have?
